More complex generics will be approved in more often in the future

At Forbes, they recently talked with Jeffrey George, global head of Novartis's Sandoz generic drug unit. Upon the approval of the generic for Lovenex, George believes that it has opened the pathway for other complex generics to be approved in the future. While the drug is not a generic, it has a complex sugar structure that is hard to copy.

George commented, "It underscores that the FDA really does have the institutional courage to approve affordable high quality alternatives to some of the more difficult to make products that are out there. There were a lot of interests lined up against this approval. It bodes well for the approval of more complex generic products in the future."

Share this article with your social network, just click below to share now!

Share |